Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA opens first offices in China

This article was originally published in The Gray Sheet

Executive Summary

U.S. agency opens offices in Beijing, Guangzhou and Shanghai, China, the week of Nov. 17 in a move approved by the U.S. State Department in March (1"The Gray Sheet" June 23, 2008, p. 5). The eight senior staffers selected to work there are inspectors and senior technical experts in foods, medicines and medical devices, HHS notes. "By having a presence in other parts of the world, we can work more closely with manufacturers and other governments, better share best practices and further ensure ... quality and safety," stated HHS Secretary Mike Leavitt, who along with FDA Commissioner Andrew von Eschenbach traveled to the three cities last week to meet with manufacturers and Chinese government officials to discuss policy and governance reforms aimed at improving the safety of food and medical products. HHS also is working to have an FDA presence in India, Europe, Latin America and the Middle East

You may also be interested in...



FDA Global Offices Update: China Approval Imminent, India On The Horizon

FDA is making headway in its efforts to establish U.S. regulatory offices overseas, with final approval in China imminent and a proposal for offices in India in final stages of U.S. approval

Basilea Stresses Derazantinib's FGFR Kinase Differentiation

Switzerland’s SIX exchange-listed drug development company, Basilea, is moving two new oncology candidates along its R&D pipeline, supported by strong revenues from two partnered anti-infective products.

 

ATMPs Put EU Cross-Border Healthcare On The Map

Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.

UsernamePublicRestriction

Register

MT026818

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel